Efficient Production of Functional Recombinant Human Neonatal Receptor (FcRn) Proteins
Posted Jun 23 2011 8:00pm
Description of Invention: Human monoclonal antibodies are becoming common therapeutics for numerous diseases, including rheumatoid arthritis, multiple sclerosis, and several different types of cancers. To improve their half-life, antibodies are engineered to have a high affinity to the Fc receptor (FcRn). This requires a reliable method to produce high yields of functional FcRn which comprises a 1:1 molar ratio of the alpha to the beta chain. Unfortunately, current methods can be difficult to implement and are not very efficient in producing functional FcRns with the 1:1 molar ratio of the alpha to the beta chain. Thus, there is a strong need for quick and economical methods of producing functional FcRn to aid in antibody development and the improvement of existing antibody therapeutics.
This technology describes a new and efficient method for producing functional human FcRn at a 1:1 molar ratio of the alpha to the beta chain. The uniqueness of this invention is that the expression of both the beta and the alpha chains is under the control of a single promoter and the correct 1: 1 molar folding of the two chains is facilitated by the intermediate flexible linker. The method is easy to scale up for producing large quantities of highly pure FcRn. Further, the inventors have recently developed a stable cell line for large scale production.
Advantages:
Efficient method of producing high yields of functional human FcRn at a 1:1 molar ratio of the alpha to the beta chain.
Stable cell line also available.
Benefits:< br/>
Improving the half-life of existing monoclonal antibodies as well as monoclonal antibodies still in development.
Research Tool — Patent protection is not being pursued for this technology.
Relevant Publication:
Feng Y, Gong R, Dimitrov DS. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor. Protein Expr Purif. 2011 Mar 29, E-pub ahead of print. [ PMID: 21453773 ]
Licensing Status: Available for licensing.
For Licensing Information Please Contact: Whitney Hastings NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: hastingw@mail.nih.gov Phone: 301-451-7337 Fax: 301-402-0220
Description of Invention:
Human monoclonal antibodies are becoming common therapeutics for numerous diseases, including rheumatoid arthritis, multiple sclerosis, and several different types of cancers. To improve their half-life, antibodies are engineered to have a high affinity to the Fc receptor (FcRn). This requires a reliable method to produce high yields of functional FcRn which comprises a 1:1 molar ratio of the alpha to the beta chain. Unfortunately, current methods can be difficult to implement and are not very efficient in producing functional FcRns with the 1:1 molar ratio of the alpha to the beta chain. Thus, there is a strong need for quick and economical methods of producing functional FcRn to aid in antibody development and the improvement of existing antibody therapeutics.
This technology describes a new and efficient method for producing functional human FcRn at a 1:1 molar ratio of the alpha to the beta chain. The uniqueness of this invention is that the expression of both the beta and the alpha chains is under the control of a single promoter and the correct 1: 1 molar folding of the two chains is facilitated by the intermediate flexible linker. The method is easy to scale up for producing large quantities of highly pure FcRn. Further, the inventors have recently developed a stable cell line for large scale production.
Advantages:
- Efficient method of producing high yields of functional human FcRn at a 1:1 molar ratio of the alpha to the beta chain.
- Stable cell line also available.
Benefits:< br/> Improving the half-life of existing monoclonal antibodies as well as monoclonal antibodies still in development.Inventors:
Dimiter S Dimitrov (NCI)
Yang Feng (NCI)
Patent Status:
HHS, Reference No. E-296-2010/0
Research Tool — Patent protection is not being pursued for this technology.
Relevant Publication:
Licensing Status:
Available for licensing.
For Licensing Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hastingw@mail.nih.gov
Phone: 301-451-7337
Fax: 301-402-0220
Ref No: 2275
Updated: 06/2011